论文部分内容阅读
目的探讨替吉奥联合奥沙利铂治疗晚期原发性肝癌的临床疗效。方法选取2012年6月—2014年6月吉安市中心人民医院收治的晚期原发性肝癌患者46例,随机分为对照组和观察组,各23例。对照组给予奥沙利铂+氟尿嘧啶(5-FU)+亚叶酸钙(CF)治疗,观察组给予替吉奥联合奥沙利铂治疗,比较两组患者的临床疗效及毒副作用发生情况。结果观察组总有效率、毒副作用发生率高于对照组,差异有统计学意义(P<0.05)。结论替吉奥联合奥沙利铂治疗晚期原发性肝癌的疗效好,毒副作用发生率稍高但是可以控制。
Objective To investigate the clinical efficacy of TIGAO and oxaliplatin in the treatment of advanced primary liver cancer. Methods Forty-six patients with advanced primary liver cancer admitted from June 2012 to June 2014 in Ji’an Central People’s Hospital were randomly divided into control group and observation group, with 23 cases in each. The control group was given oxaliplatin + 5-fluorouracil (5-FU) + leucovorin (CF). The observation group was treated with tiotropium combined with oxaliplatin. The clinical efficacy and side effects of the two groups were compared. Results The total effective rate and the incidence of toxic and side effects in the observation group were significantly higher than those in the control group (P <0.05). Conclusion Treatment of advanced primary hepatocellular carcinoma with tiotropium combined with oxaliplatin is effective and the incidence of toxic and side effects is slightly higher but can be controlled.